CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
CBTN's innovative approach ensures data remains open to the global research community while facilitating collaboration with commercial entities like Day One.PHILADELPHIA, Dec. 16, 2024 /PRNewswire/ -- The Children's Brain Tumor Network (CBTN), a consortium of leading pediatric brain tumor research institutions, announces that it has formed a groundbreaking partnership with Day One Biopharmaceuticals (Day One), a company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. This new partnership between CBTN and Day One aims to accelerate the development of new treatments for children with brain tumors. It leverages the robust Pediatric Brain Tumor Atlas (PBTA), a comprehensive resource containing genomic, clinical, and imaging data from over 7,600 pediatric brain tumor patients. Day One will utilize this data set to design clinical trials.
費城，2024年12月16日 /PRNewswire/ — 由領先的兒科腦腫瘤研究機構組成的聯盟兒童腦腫瘤網絡（CBTN）宣佈，它已與Day One Biopharmaceuticals（Day One）建立了開創性的合作伙伴關係，該公司致力於爲所有年齡段患有危及生命的疾病的人開發和商業化靶向療法。CBTN和Day One之間的這種新夥伴關係旨在加速腦腫瘤兒童新療法的開發。它利用了強大的兒科腦腫瘤地圖集（PBTA），該綜合資源包含來自7,600多名兒科腦腫瘤患者的基因組、臨床和成像數據。第一天將利用這個數據集來設計臨床試驗。
"We are deeply grateful for this partnership, which reflects a shared commitment to advancing therapies for children with brain tumors," said Dr. Angela Waanders, LLG Study Chair for the Children's Brain Tumor Network. "Uniting CBTN resources with Day One's innovative approach accelerates the delivery of clinical trials to children worldwide."
兒童腦腫瘤網絡LLG研究主席Angela Waanders博士說：「我們對這種夥伴關係深表感謝，這反映了我們對推進腦腫瘤兒童治療的共同承諾。」「將CBTN資源與Day One的創新方法相結合，可以加快向全球兒童提供臨床試驗的速度。」
Together, CBTN and Day One aim to accelerate the development of new treatments for children with brain tumors.
CBTN和Day One的共同目標是加快腦腫瘤兒童新療法的開發。
CBTN's innovative approach ensures data remains open to the global research community while facilitating collaboration with commercial entities like Day One.
CBTN的創新方法確保了數據對全球研究界的開放，同時促進了與Day One等商業實體的合作。
"CBTN's commitment to open access data, coupled with their world-class expertise in pediatric brain tumors, makes them an ideal partner for Day One," said Elly Barry, M.D., chief medical officer, Day One Biopharmaceuticals. "This collaboration should allow us to better design clinical trials to potentially bring new therapies to children in need."
Day One Biopharmaceuticals首席醫學官艾莉·巴里萬博士表示：「CBTN對開放獲取數據的承諾，加上他們在兒科腦腫瘤方面的世界一流專業知識，使他們成爲第一天的理想合作伙伴。」「這種合作應該使我們能夠更好地設計臨床試驗，從而有可能爲有需要的兒童帶來新的療法。」
The partnership between CBTN and Day One also paves the way for developing trial-ready external control arms in pediatric clinical studies.
CBTN和Day One之間的合作也爲在兒科臨床研究中開發可供試驗的外部控制武器鋪平了道路。
About Children's Brain Tumor Network
關於兒童腦瘤網絡
CBTN is a collaborative research enterprise created to ensure that no child suffers or dies from a brain tumor. The 35 international member institutions comprising CBTN have enrolled more than 7,000 study participants and more than 70,000 biospecimen samples to create the world's most comprehensive repository of childhood brain tumors. To learn more, visit cbtn.org.
CBTN是一家合作研究企業，旨在確保沒有兒童患有或死於腦瘤。組成CBTN的35個國際成員機構已經招收了7,000多名研究參與者和70,000多個生物標本樣本，以創建世界上最全面的兒童腦腫瘤資料庫。要了解更多信息，請訪問 cbtn.org。
Press Contact
Whitney Rife
[email protected] | 609-947-6809
新聞聯繫人
惠特尼·裏夫
[電子郵件保護] | 609-947-6809
SOURCE Children's Brain Tumor Network
來源：兒童腦瘤網絡